JP2011526887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526887A5 JP2011526887A5 JP2011516261A JP2011516261A JP2011526887A5 JP 2011526887 A5 JP2011526887 A5 JP 2011526887A5 JP 2011516261 A JP2011516261 A JP 2011516261A JP 2011516261 A JP2011516261 A JP 2011516261A JP 2011526887 A5 JP2011526887 A5 JP 2011526887A5
- Authority
- JP
- Japan
- Prior art keywords
- infection
- composition
- caused
- resistant
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000009910 diseases by infectious agent Diseases 0.000 claims 10
- 229940076185 Staphylococcus aureus Drugs 0.000 claims 5
- 241000191967 Staphylococcus aureus Species 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 4
- 229960003085 meticillin Drugs 0.000 claims 4
- 229940037467 Helicobacter pylori Drugs 0.000 claims 2
- 241000590002 Helicobacter pylori Species 0.000 claims 2
- 229960000282 Metronidazole Drugs 0.000 claims 2
- 229940049954 Penicillin Drugs 0.000 claims 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 229940031000 Streptococcus pneumoniae Drugs 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 229960003165 Vancomycin Drugs 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- 229960000626 benzylpenicillin Drugs 0.000 claims 2
- 229940049920 malate Drugs 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010060803 Diabetic foot infection Diseases 0.000 claims 1
- 230000035695 Efflux Effects 0.000 claims 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims 1
- 206010036410 Postoperative wound infection Diseases 0.000 claims 1
- 206010040872 Skin infection Diseases 0.000 claims 1
- 229940037645 Staphylococcus epidermidis Drugs 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 206010046577 Urinary tract infection Diseases 0.000 claims 1
- 201000005661 acute cystitis Diseases 0.000 claims 1
- 200000000017 bloodstream infection Diseases 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- HPWUWKIHYFPDGW-LBPRGKRZSA-N COc(c(N(C[C@H](C1)N)CC1=C)ccc12)c1N(C1CC1)C=C(C(O)=O)C2=O Chemical compound COc(c(N(C[C@H](C1)N)CC1=C)ccc12)c1N(C1CC1)C=C(C(O)=O)C2=O HPWUWKIHYFPDGW-LBPRGKRZSA-N 0.000 description 2
- AVPQPGFLVZTJOR-UHFFFAOYSA-N CC(CC(C1)N)CN1c(c(OC)c1N(C2CC2)C=C2C(O)=O)ccc1C2=O Chemical compound CC(CC(C1)N)CN1c(c(OC)c1N(C2CC2)C=C2C(O)=O)ccc1C2=O AVPQPGFLVZTJOR-UHFFFAOYSA-N 0.000 description 1
- JUJVJGOLGIJVHU-UHFFFAOYSA-N COc(c(N1CC2(CC2)CCC1)ccc12)c1N(C1CC1)C=C(C(O)=O)C2=O Chemical compound COc(c(N1CC2(CC2)CCC1)ccc12)c1N(C1CC1)C=C(C(O)=O)C2=O JUJVJGOLGIJVHU-UHFFFAOYSA-N 0.000 description 1
Claims (12)
- 下記式：
- 前記感染症が、メチシリン耐性表皮ブドウ球菌(Staphylococcus epidermidis)によって引き起こされる、請求項１に記載の組成物。
- 前記感染症が、クラリスロマイシン耐性ヘリコバクターピロリ(Helicobacter pylori)またはメトロニダゾール耐性ヘリコバクターピロリ(Helicobacter pylori)によって引き起こされる、請求項１に記載の組成物。
- 前記感染症が、メチシリン耐性黄色ブドウ球菌(Staphylococcus aureus)、排出関連(efflux-related)メチシリン耐性黄色ブドウ球菌(Staphylococcus aureus)、バンコマイシン低感受性黄色ブドウ球菌(vancomycin-intermediate Staphylococcus aureus)、ヘテロバンコマイシン低感受性黄色ブドウ球菌(hetero-vancomycin-intermediate Staphylococcus aureus)、またはバンコマイシン耐性黄色ブドウ球菌(vancomycin-resistant Staphylococcus aureus)によって引き起こされる、請求項１に記載の組成物。
- 前記感染症が、市中感染型メチシリン耐性黄色ブドウ球菌(community-associated Staphylococcus aureus)によって引き起こされる、請求項４に記載の組成物。
- 前記感染症が、ペニシリン耐性肺炎連鎖球菌(Streptococcus pneumoniae)によって引き起こされる、請求項１に記載の組成物。
- 前記感染症が、メチシリン、バンコマイシン、およびペニシリンの少なくとも一種に耐性がある、多剤耐性肺炎連鎖球菌(Streptococcus pneumoniae)によって引き起こされる、請求項１に記載の組成物。
- 前記感染症が、糖尿病足感染症、手術創感染症、尿路感染症、血流感染症、院内感染性肺炎、市中肺炎、または皮膚感染症である、請求項４に記載の組成物。
- 前記化合物が塩の形態である、請求項１〜８のいずれか１項に記載の組成物。
- 前記化合物がリンゴ酸塩の形態である、請求項９に記載の組成物。
- 前記化合物がリンゴ酸塩０．５水和物の形態である、請求項１０に記載の組成物。
- 前記化合物が下記式：
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7729308P | 2008-07-01 | 2008-07-01 | |
| US61/077,293 | 2008-07-01 | ||
| PCT/US2008/075549 WO2010002415A1 (en) | 2008-07-01 | 2008-09-08 | Treatment of antibiotic-resistant bacteria infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526887A JP2011526887A (ja) | 2011-10-20 |
| JP2011526887A5 true JP2011526887A5 (ja) | 2011-12-01 |
Family
ID=41464848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516261A Pending JP2011526887A (ja) | 2008-07-01 | 2008-09-08 | 抗生物質耐性菌感染症の治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8211909B2 (ja) |
| EP (1) | EP2303271B1 (ja) |
| JP (1) | JP2011526887A (ja) |
| KR (2) | KR20110044168A (ja) |
| CN (1) | CN101618038B (ja) |
| AU (1) | AU2008358909B2 (ja) |
| CA (1) | CA2728328C (ja) |
| EA (1) | EA018653B1 (ja) |
| HK (1) | HK1139049A1 (ja) |
| NZ (1) | NZ588898A (ja) |
| TR (1) | TR201820964T4 (ja) |
| TW (1) | TWI375558B (ja) |
| WO (1) | WO2010002415A1 (ja) |
| ZA (1) | ZA201100616B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101392808B1 (ko) * | 2011-12-30 | 2014-05-12 | 순천대학교 산학협력단 | 식물 추출물 또는 이의 분획물을 포함하는 항균용 조성물 |
| CN103145615B (zh) * | 2013-03-20 | 2015-07-29 | 浙江医药股份有限公司 | 一种奈诺沙星螯合物的后处理方法 |
| KR101392810B1 (ko) * | 2013-09-25 | 2014-05-12 | 순천대학교 산학협력단 | 된장풀 추출물 또는 이의 분획물을 포함하는 항균용 조성물 |
| US9492374B2 (en) | 2015-03-25 | 2016-11-15 | Jose Rafael Salinas Andrade | Composition and method for treatment of ulcers |
| CN105368825B (zh) * | 2015-10-14 | 2019-09-10 | 华东医院 | 幽门螺杆菌抗生素耐药性分析试剂盒及耐药性检测方法 |
| JP7203442B2 (ja) * | 2017-12-11 | 2023-01-13 | デノバメド インク． | 細菌感染症の局所処置のための５－（２，５－ビス（４－クロロ－２－イソプロピルフェニル）チオフェン－３－イル）－１ｈ－テトラゾール |
| CN111979292B (zh) * | 2020-07-27 | 2022-08-05 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种同时携带多重耐药基因cfr和lsa(E)的MRSA的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US100800A (en) | 1870-03-15 | Improvement in riding attachments for plows | ||
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| WO1999014214A1 (en) | 1997-09-15 | 1999-03-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| US6387928B1 (en) | 1997-09-15 | 2002-05-14 | The Procter & Gamble Co. | Antimicrobial quinolones, their compositions and uses |
| US6348624B1 (en) | 1998-01-09 | 2002-02-19 | The Procter & Gamble Co. | Process for making certain benzoic acid compounds |
| AU2905702A (en) | 2000-12-14 | 2002-06-24 | Procter & Gamble | Cyclization process step in the making of quinolones and naphthyridines |
| US6900224B2 (en) | 2002-07-31 | 2005-05-31 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
| US6803469B2 (en) | 2002-08-05 | 2004-10-12 | The Procter & Gamble Company | Process for preparing quinolone antibiotic intermediates |
| WO2005026145A2 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| KR101030202B1 (ko) | 2006-03-28 | 2011-04-22 | 워너 칠콧 컴퍼니 엘엘씨 | 퀴놀론 중간체의 제조를 위한 수소화물 환원 방법 |
| KR101102288B1 (ko) * | 2006-03-28 | 2012-01-03 | 워너 칠콧 컴퍼니 엘엘씨 | (3ｓ,5ｓ)-7-(3-아미노-5-메틸-피페리디닐)-1-사이클로프로필-1,4-다이하이드로-8-메톡시-4-옥소-3-퀴놀린카르복실산의 말레이트 염 및 다형체 |
| CA2647454A1 (en) | 2006-03-28 | 2007-10-04 | The Procter & Gamble Company | A coupling process for preparing quinolone intermediates |
| US8658183B2 (en) * | 2007-08-09 | 2014-02-25 | Taigen Biotechnology Company, Ltd. | Antimicrobial parenteral formulation |
| JP2011528354A (ja) * | 2008-07-15 | 2011-11-17 | タイゲン バイオテクノロジー カンパニー，リミテッド | 抗生物質 |
-
2008
- 2008-09-08 KR KR1020107025547A patent/KR20110044168A/ko not_active Application Discontinuation
- 2008-09-08 CA CA2728328A patent/CA2728328C/en active Active
- 2008-09-08 NZ NZ588898A patent/NZ588898A/xx unknown
- 2008-09-08 JP JP2011516261A patent/JP2011526887A/ja active Pending
- 2008-09-08 US US12/206,060 patent/US8211909B2/en active Active
- 2008-09-08 EA EA201170121A patent/EA018653B1/ru unknown
- 2008-09-08 AU AU2008358909A patent/AU2008358909B2/en active Active
- 2008-09-08 EP EP08821583.5A patent/EP2303271B1/en active Active
- 2008-09-08 KR KR1020147036073A patent/KR20150006080A/ko not_active Application Discontinuation
- 2008-09-08 TR TR2018/20964T patent/TR201820964T4/tr unknown
- 2008-09-08 WO PCT/US2008/075549 patent/WO2010002415A1/en active Application Filing
- 2008-09-09 TW TW097134583A patent/TWI375558B/zh active
- 2008-09-26 CN CN2008101700068A patent/CN101618038B/zh active Active
-
2010
- 2010-05-17 HK HK10104822.4A patent/HK1139049A1/xx unknown
-
2011
- 2011-01-25 ZA ZA2011/00616A patent/ZA201100616B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526887A5 (ja) | ||
| JP2011102304A5 (ja) | ||
| JP2007501251A5 (ja) | ||
| JP2015512386A5 (ja) | ||
| JP2012513467A5 (ja) | ||
| JP2013253094A5 (ja) | ||
| CL2007002866A1 (es) | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m | |
| JP2016507532A5 (ja) | ||
| WO2008116813A3 (en) | Combination medicaments for treating bacterial infections | |
| JP2013541333A5 (ja) | ||
| JP2009503024A5 (ja) | ||
| EP2535353A8 (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
| JP2012506870A5 (ja) | ||
| JP2008520660A5 (ja) | ||
| JP2015504921A5 (ja) | ||
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| WO2009022185A3 (en) | 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use | |
| JP2012501349A5 (ja) | ||
| JP2008546824A5 (ja) | ||
| JP2011515406A5 (ja) | ||
| JP2009503021A5 (ja) | ||
| WO2007062333A3 (en) | New pleuromutilin derivative and its use | |
| JP2008543964A5 (ja) | ||
| JP2011528354A5 (ja) | ||
| JP2008521783A5 (ja) |